How Webster was paid
$7.5M in total for fiscal 2026, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Incentive | Other | Total |
|---|---|---|---|---|---|
| Brian WebsterPresident, Chief Executive Officer & Director | $765,000 | $5,722,937 | $918,000 | $95,966 | $7,501,904 |
| Traci S. UmbergerGeneral Counsel, Chief Administrative Officer & Director | $500,000 | $1,907,662 | $360,000 | $93,756 | $2,861,418 |
| Al FordChief Commercial Officer | $500,000 | $1,907,662 | $360,000 | $24,424 | $2,792,086 |
| Vaseem MahboobChief Financial Officer | $470,000 | $1,430,747 | $338,400 | $28,197 | $2,267,344 |
What changed and why
- $7.5M2026 CEO total compensation was $7,501,904, versus $18,890,730 in 2025.
- $5.7M$5,722,937 of the CEO’s 2026 compensation came from stock awards, compared with no stock awards in 2025.
- 75%At least 75% of annual target total direct equity compensation was tied to absolute and relative long-term performance goals.
- $918K$918,000 was the CEO’s 2026 non-equity incentive compensation, reflecting annual performance-based cash bonuses.
- $765KMarch 6, 2025 base-salary increases raised the CEO’s annual salary to $765,000 and the General Counsel’s to $500,000.
- Al Ford became a named executive officer for the first time in fiscal 2026.
Other Kestra Medical Technologies proxy statements
- 2025 proxy statement
Brian Webster paid $18.9M.
Filed Jul 22, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.